China Rabies Vaccine After Dog Bite And Scratch Injuries Manufacturer, Supplier, Factory

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., a trusted China-based manufacturer of human biological products, offers the Rabies Vaccine After Dog Bite And Scratch Injuries—a highly immunogenic Vero cell‑grown inactivated vaccine designed for rapid post‑exposure protection. Clinical data confirm 100% antibody seroconversion within 14 days, a key metric that far exceeds WHO’s minimum protective threshold. With an annual output of ~22 million doses and a cumulative supply exceeding 100 million, this vaccine ensures uninterrupted availability for emergency departments, veterinary clinics, and public health programs worldwide. Its dual‑formulation portfolio (conventional and serum‑free) addresses diverse safety and cost requirements, making it a preferred choice for government tenders and cross‑border procurement.

Product Introduction and Target Indications

The Rabies Vaccine After Dog Bite And Scratch Injuries is a freeze‑dried, inactivated rabies vaccine cultivated on Vero cells, specifically indicated for post‑exposure prophylaxis (PEP) in individuals who have sustained dog bites, scratches, or mucosal contamination. As a leading supplier of rabies biologics, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. produces this vaccine in GMP‑certified facilities that undergo annual inspections by China’s National Medical Products Administration (NMPA). The vaccine contains no preservatives and is presented as a white porous cake that reconstitutes to a clear liquid. It is suitable for both Category II (non‑bleeding bites/scratches) and Category III (bleeding bites or mucous membrane exposure) injuries, as defined by WHO exposure classification. When combined with rabies immunoglobulin (20 IU/kg) for severe exposures, it provides a comprehensive protective barrier against a disease that is almost invariably fatal once clinical signs appear.

Immunogenicity and Antibody Response

Robust humoral immunity is the cornerstone of effective rabies prevention. The Rabies Vaccine After Dog Bite And Scratch Injuries consistently elicits high‑titre neutralising antibodies, with a 100% seroconversion rate observed by day 14 after the first dose. The actual mean potency of the conventional version reaches approximately 6.0 IU per dose—well above the WHO‑required minimum of 2.5 IU/dose. For the serum‑free formulation, post‑immunisation geometric mean antibody concentrations (GMC) remain significantly higher than the protective level of 0.5 IU/mL, with immune persistence documented for over three months. This rapid and durable response is critical for exposed patients, as every hour counts in preventing viral migration to the central nervous system.

Key immunological highlights include:

● Seroconversion timeline: 100% by day 14, aligning with WHO accelerated schedule recommendations.

● Booster effect: The 5‑dose regimen (0, 3, 7, 14, 28 days) induces anamnestic responses; the serum‑free version also supports the simplified 4‑dose WHO schedule without compromising efficacy.

● Cross‑neutralisation: Antibodies generated are effective against diverse field strains of rabies virus, as confirmed by extensive quality control testing.

Product Specifications and Formulations

To meet varied clinical and economic needs, the Rabies Vaccine After Dog Bite And Scratch Injuries is available in two technologically distinct versions. The conventional Vero cell product uses the aG strain and has a long track record of safety and cost‑effectiveness. The innovative serum‑free version employs the PV‑2061 strain and eliminates bovine serum from the entire production chain—from cell revival to virus cultivation—thereby reducing the risk of allergic reactions and adventitious agent contamination. Both are freeze‑dried powders, each vial reconstitutes to 1.0 mL for intramuscular injection. The table below summarises their key parameters:

Safety Profile and Adverse Reactions

Safety is paramount for any vaccine, especially when administered in emergency settings. The Rabies Vaccine After Dog Bite And Scratch Injuries has demonstrated an excellent safety record across millions of doses. In clinical trials and post‑marketing surveillance, adverse reactions are predominantly mild (Grade 1‑2) and transient, such as local pain, redness, or low‑grade fever. No Grade 4 or above severe adverse events have been reported. The serum‑free version offers an additional safety advantage by eliminating bovine serum, which is a known source of allergic sensitisation and batch‑to‑batch variability. Moreover, the vaccine is free from thiomersal and other preservatives, making it suitable for patients with sensitivity to such additives.

● Local reactions: Pain at injection site (most common), usually resolves within 48 hours.

● Systemic reactions: Mild headache, fatigue, or myalgia occur in <5% of recipients.

● Contraindications: Severe acute febrile illness; however, post‑exposure vaccination should not be delayed even in the presence of minor infections.

In the event of a Category III exposure, the vaccine can be co‑administered with rabies immunoglobulin at a separate anatomical site, with no increased safety concerns.

Vaccination Schedule and Administration

Correct administration is crucial for optimal protection. The Rabies Vaccine is given by intramuscular injection into the deltoid (or anterolateral thigh in young children) with a 1.0 mL dose. The standard Essen regimen consists of five doses on days 0, 3, 7, 14, and 28 post‑exposure. For travel medicine or resource‑limited settings, the WHO‑approved 4‑dose schedule (days 0, 3, 7, and 14) is also supported by the serum‑free formulation, providing flexibility without compromising immunogenicity. The vaccine can be stored at 2‑8°C for up to 36 months, and the freeze‑dried powder should be reconstituted immediately before use with the supplied diluent. For patients who have previously been fully vaccinated, a reduced booster schedule may be applied, but this should be determined by a healthcare professional based on individual risk assessment.

Global Market Presence and Supply Capacity

AIM Honor is not only a domestic leader but also an influential global supplier of rabies vaccines. The Rabies Vaccine After Dog Bite And Scratch Injuries is exported to more than 20 countries across South America, Central Asia, South Asia, Africa, and Southeast Asia. With an annual production capacity of approximately 22 million doses, the company guarantees stable supply for both emergency stockpiles and routine immunisation programmes. AIM Vaccine has established cooperative agreements with governments in Pakistan, Kenya, and Egypt, and actively participates in international tenders. The company’s participation in major exhibitions such as CPHI Europe, CPHI China, TIHE, and VIF World 2025 reflects its commitment to global health partnerships. For bulk buyers, flexible packaging options and dedicated logistics support ensure timely delivery even to remote regions.

Quality Management and Regulatory Approvals

Every batch of the Rabies Vaccine After Dog Bite And Scratch Injuries is manufactured under strict quality control systems that comply with Chinese and international pharmacopoeial standards. The conventional version holds National Drug Approval Number S20073014, while the serum‑free version has successfully completed Phase III trials and received market application acceptance (No. CXSS2500044) from the NMPA. The production lines are regularly inspected by national and provincial regulators, with the most recent GMP certification granted in December 2025. AIM Vaccine’s quality management system covers the entire supply chain—from raw material sourcing to final product release—and incorporates advanced testing for potency, sterility, and endotoxin levels. This rigorous oversight ensures that every vial meets the highest safety and efficacy benchmarks, giving healthcare providers and patients full confidence in the vaccine’s performance.

Frequently Asked Questions (FAQ)

Q: What is the recommended time window for administering the vaccine after a dog bite or scratch?

A: The vaccine should be initiated as soon as possible after exposure, ideally within 24 hours. However, even if more than 24 hours have passed, vaccination is still highly recommended, as the incubation period of rabies can vary from weeks to months. For Category III exposures, rabies immunoglobulin should also be given concurrently with the first dose. There is no upper time limit for initiating PEP—it is never too late to start.

Q: Can the serum‑free version be used interchangeably with the conventional version for sequential doses?

A: Yes, both versions of the vaccine are based on inactivated rabies virus and elicit similar neutralising antibody responses. According to available data, sequential vaccination with different brands or formulations is acceptable and does not reduce immunogenicity. However, to minimise any potential variability, it is recommended to complete the full course with the same product whenever possible.

Q: Are there any special precautions for pregnant or lactating women?

A: Rabies is a uniformly fatal disease once symptoms develop, so post‑exposure vaccination is not contraindicated during pregnancy or lactation. No specific adverse effects on pregnancy or the foetus have been reported with the use of inactivated rabies vaccines. Pregnant women should receive the vaccine if indicated, and the decision should be made in consultation with a healthcare provider.

Q: How should the vaccine be stored and transported?

A: The freeze‑dried vaccine must be stored at 2‑8°C, protected from light, and must never be frozen. During transportation, cold‑chain integrity must be maintained using validated refrigerated containers. The diluent should be stored at room temperature or in the same cold chain, but the reconstituted vaccine should be used immediately or within a few hours if kept at 2‑8°C.

Q: What is the difference between the conventional and serum‑free versions in terms of cost?

A: The conventional version benefits from mature production technology and larger economies of scale, making it more cost‑effective for large‑scale public health programmes. The serum‑free version, while slightly higher in cost due to its advanced cell culture process, offers added safety benefits (zero bovine serum) and is particularly suitable for patients with allergy concerns or for markets that require the highest purity standards. Both options are competitively priced for international tenders.

Partner with a Trusted Supplier

Choosing the right partner for rabies vaccine procurement is as critical as the vaccine itself. AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. combines decades of manufacturing expertise, a robust quality system, and a proven export track record. Whether you require the Rabies Vaccine After Dog Bite And Scratch Injuries for emergency stockpiles, routine clinic use, or mass immunisation campaigns, our dedicated sales team provides end‑to‑end support—from regulatory documentation to logistics coordination. Contact us today to discuss your specific requirements and to receive a competitive quotation. With AIM Honor, you secure not only a world‑class vaccine but also a long‑term partnership committed to global rabies elimination.